An interventional study of Neoadjuvant Radiotherapy/Chemoradiotherapy Followed by Surgery and Surgery Followed by Adjuvant Radiotherapy/Chemoradiotherapy in Malignant Tumor of Lacrimal Drainage Structure, sponsored by Eye & ENT Hospital of Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-25.
Sponsored by Eye & ENT Hospital of Fudan University · Not applicable, Interventional, and Treatment
The treatment for malignant lacrimal sac tumors is difficult and the prognosis is poor. The conventional strategy is surgical resection followed by adjuvant radiotherapy with or without concurrent chemotherapy. This approach has many drawbacks including positive surgical margins due to large tumor size, distant metastasis due to intraoperative squeeze, and implant exposure due to high doses of radiation. In previous research, the investigators innovatively adopted neoadjuvant radiotherapy (or chemoradiotherapy) and withdrew radiotherapy after surgery. Preoperative radiotherapy can effectively reduce the tumor size and encapsulate the tumor in a fibrotic cyst, and therefore enables en-bloc excision of the tumor and simultaneous orbital reconstruction. This multidisciplinary approach can reduce the risk of recurrence and metastasis, lower the dose of radiation, and avoid implant exposure after reconstruction.
In order to compare the long-term outcomes between neoadjuvant radiotherapy and conventional treatment approach, the investigators will prospectively recruit 94 patients with malignant lacrimal sac tumors and randomly assign these subjects into the study group (neoadjuvant radiotherapy, 47 cases) and the control group (conventional treatment, 47 cases). The primary outcomes include overall survival, disease-free survival, distant metastasis-free survival, and locoregional control at 2-year, 5-year and 10-year intervals. The secondary outcomes include ocular functions (visual acuity and diplopia, tear film stability and tear secretion, globe dystopia and motility, and corneal topography), acute and chronic radiation-related toxicity, cosmesis (medial canthal tendon dystopia and eyelid retraction), and assessment of quality of life.
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's planned enrollment of 94 is above the median of 50 across 7,253 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Eye & ENT Hospital of Fudan University is the lead sponsor of 121 studies on the registry; 67 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Neoadjuvant Radiotherapy/Chemoradiotherapy Followed by Surgery
Other: Neoadjuvant Radiotherapy/Chemoradiotherapy Followed by Surgery
Surgery Followed by Adjuvant Radiotherapy/Chemoradiotherapy
Other: Surgery Followed by Adjuvant Radiotherapy/Chemoradiotherapy
After assigned into the study group, subjects will be conducted with incisional biopsy. Based on the tumor type and tumor stage, subjects will be conducted with neoadjuvant radiotherapy/chemoradiotherapy followed by radical surgery and simultaneous orbital reconstruction. After surgery, adjuvant chemotherapy will be determined based on the tumor histology, local tumor invasiveness, proximity of the surgical margins from the tumor, and pronouncement of tumor margins on permanent section tissue review.
After assignment into the control group, subjects will receive radical surgery without simultaneous orbital reconstruction. Adjuvant radiotherapy / chemoradiotherapy will initiate within two weeks after surgery. Both the radiotherapy and chemoradiotherapy should be comparable between the study group and the control group when tumor characteristics in these two groups are identical.
overall survival at 2-year interval
living subjects
Time frame: 2 years
overall survival at 5-year interval
living subjects
Time frame: 5 years
overall survival at 10-year interval
living subjects
Time frame: 10 years
disease-free survival at 2-year interval
tumor-free subjects
Time frame: 2 years
disease-free survival at 5-year interval
tumor-free subjects
Time frame: 5 years
disease-free survival at 10-year interval
tumor-free subjects
Time frame: 10 years
distant metastasis-free survival at 2-year interval
living subjects with no distant metastasis
Time frame: 2 years
distant metastasis-free survival at 5-year interval
living subjects with no distant metastasis
Time frame: 5 years
distant metastasis-free survival at 10-year interval
living subjects with no distant metastasis
Time frame: 10 years
locoregional control at 2-year interval
living subjects without local recurrence or local metastasis
Time frame: 2 years
locoregional control at 5-year interval
living subjects without local recurrence or local metastasis
Time frame: 5 years
locoregional control at 10-year interval
living subjects without local recurrence or local metastasis
Time frame: 10 years
Visual Acuity
Best-corrected visual acuity (BCVA) will be measured under standardized lighting conditions in the room, and will be converted to logarithm of the minimum angle of resolution (logMAR) values for statistical analysis.
Time frame: up to 2 years
Subjective Diplopia After Surgery
Subjective diplopia will be assessed by categorizing patients according to four grades: no diplopia (absent), diplopia when the patient is tired or awakening (intermittent), diplopia at extremes of gaze (inconstant), and continuous diplopia in the primary or reading position (constant). A change of one grade is considered to be clinically relevant.
Time frame: up to 2 years
Number of Participants with Acute Radiation-Related Toxicity
Acute radiation-related toxicity is defined as events occurring within 1 month after start of radiotherapy, and will be prospectively graded by the treating radiation oncologist according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5).
Time frame: 1 month
Number of Participants with Chronic Radiation-Related Toxicity
Chronic radiation-related toxicity is defined as events occurring or persisting \> 3 months after start of radiotherapy, and will be prospectively graded by the treating radiation oncologist according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5).
Time frame: up to 2 years
Health-Related Quality of life
The health-related quality of life will be assessed based on the EORTC (European Organisation for Research and Treatment of Cancer) Quality of Life Questionnaire Core 30 (QLQ-C30) downloaded from https://www.eortc.org. This 30-item questionnaire includes five functional scales, three symptom scales, a global health status / QoL scale, and six single items. The multi-item scales include a different set of items. Each item includes four subscales, namely "Not at all" (1 point), "A little" (2 points), "Quite a bit" (3 points) and "Very much" (4 points). The score will be recorded during each follow-up, and data will be analyzed for comparison between the study group and the control group.
Time frame: up to 10 years
Ophthalmic Cancer-Related Quality of life
The ophthalmic cancer-related quality of life will be assessed based on the EORTC (European Organisation for Research and Treatment of Cancer) Quality of Life Questionnaire Ophthalmic Cancer Module 30 (QLQ-OPT30) downloaded from https://www.eortc.org. The QLQ-OPT30 comprises of 30 questions assessing vision impairment (9 items), functional problems due to vision impairment (8 items), eye symptoms (6 items), worry about recurrent disease (2 items), problems with appearance (1 items), problems driving (2 items), headache (1 item), problems reading (1 item). Each item includes four subscales, namely "Not at all" (1 point), "A little" (2 points), "Quite a bit" (3 points) and "Very much" (4 points). The score will be recorded during each follow-up, and data will be compared between the study group and the control group.
Time frame: up to 10 years
Plan to share: Yes
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eye & ENT Hospital of Fudan University